Gastroenterology

GI symptoms manifest in children with COVID-19 more than they do in adult patients.

Treatment failure occurred in 10% of the intensive treatment group compared to 28% in the standard treatment group

Eli Lilly and Company is expected to apply for a Biologics License Application in the first half of 2022.

At least 3 companies have presented later phase data on live microbiota therapies for treating recurrent C difficile infections in 2021.

The US recommended HBV vaccines to be part of the infant immunization plan in 1991.

The rigidity of hospital settings and a lack of awareness prevents better hepatitis C virus diagnoses in the homeless population.

Bincy Abraham, MD, led the State of Science program on C difficile infections.

The treatment also has potential in Crohn's disease and rheumatoid arthritis.

The State of the Science events allows experts to come together to update on recent research for CDI.

Nearly half of patients not in clinical remission achieved de novo clinical remission after 1 year in the maintenance study.

The recombinant vaccine resulted in higher rates of seroprotection in all subjects, particularly those 45 years and older.

IBD patients also were more likely to have bloody diarrhea and abdominal pain.

Endoscopies can be costly, invasive, and time-consuming as a way to assess disease active and infliximab efficacy in IBD.

Recent studies have indicated more community spread of C difficile infections.

More global studies on the prevalence of celiac disease are needed outside of the US and Europe.

Several companies are testing live microbiota therapies for C difficile infections.

Diagnosing patients with classic GERD symptoms such as heartburn and regurgitation call for an 8-week trial of empiric proton pump inhibitors once daily prior to a meal.

In a study presented at ACG, investigators focus on quality of life improvements for patients with irritable bowel syndrome.

Only 5 individuals of 195 who received liver transplantation had HCC reoccur more than 3 years following surgery.

Students with IBS were also linked to depression and anxiety symptoms.

There has recently been more community spread of C difficile infections.

Various factors decreased the likelihood of achieving SVR, including male gender, cirrhosis, recent injecting drug use, and previous DAA treatment.

There were no serious adverse events or treatment-related adverse events identified in either treatment group.

Fecal microbiota transplantation recipients did gain weight following the procedure.

Investigators found 11.9% of patients with IBD in a survey were considered vaccine hesitant.